Tango Therapeutics announced its Q1 2026 financial results, reporting a net loss of $45.5 million and holding $380 million in cash to fund operations into 2028. The company is advancing its cancer drug vopimetostat, focusing on pivotal trials in pancreatic cancer and combination studies with RAS(ON) inhibitors, with initial clinical data expected in 2026. Leadership changes and new appointments aim to support late-stage development. Upcoming milestones include clinical data updates for vopimetostat and TNG456, and initiation of new combination trials in the second half of 2026.
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
